Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by Walleye101on Apr 05, 2007 7:52pm
165 Views
Post# 12559659

Some D&D

Some D&DI don't know how much research anyone on this board has done on this company. From my understanding they have taken two different drugs and as a "regiment" administered them. They made up a name for the use of the compounds "NTX(TM)-265" and made it their own. Does any of you know anything about the two drugs. Well here is a couple links on the use of these compounds. https://www.rice.edu/~jenky/sports/epo.html https://www.mesomorphosis.com/steroid-profiles/human-chorionic-gonadotropin.htm Just wondering what these guys originally were working on when they realized what else could be achieved. One other point I would like to bring up, any one done the math on the financials. There seems to be 8,296,000 more shares this year. Outstanding shares as of April 4, 2007, are 68,072,364 SCT recorded a net loss of $4,759,929 (nine cents per common share) for the fiscal year ended Dec. 31, 2006. As of March 31, 2005 SCT's outstanding shares totaled 53,066,364 common shares and 6,720,000 Class B shares. SCT recorded a net loss for the three month period ended March 31, 2005 of $595,685 or $0.01 per common share. Total of 59,786,364 shares Anybody on this thread know where these shares came from? I know one thing. They figured out how to spend money! Any comments? As always, accept for the facts, the above comments are my own insightful opinions.
Bullboard Posts